The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 22, 2019
Filed:
Aug. 13, 2018
Applicant:
Som Innovation Biotech, S.l., Barcelona, ES;
Inventors:
Marc Centellas Casado, Barcelona, ES;
Raúl Insa Boronat, Barcelona, ES;
Núria Reig Bolano, Barcelona, ES;
Nuria Gavaldà Batalla, Barcelona, ES;
Assignee:
SOM Innovation Biotech, S.L., Barcelona, ES;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/165 (2006.01); C07D 263/58 (2006.01); C07D 263/20 (2006.01); A61K 31/198 (2006.01); A61K 45/06 (2006.01); A61K 31/12 (2006.01); A61K 31/353 (2006.01); A61K 31/423 (2006.01); A61K 31/603 (2006.01); A61K 31/192 (2006.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 31/12 (2013.01); A61K 31/192 (2013.01); A61K 31/353 (2013.01); A61K 31/423 (2013.01); A61K 31/603 (2013.01); A61K 45/06 (2013.01);
Abstract
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.